🇺🇸 FDA
Pipeline program

Pembrolizumab

7339-001

Phase 3 mab completed

Quick answer

Pembrolizumab for Ovarian Cancer is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Ovarian Cancer
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials